Aspira Women’s Health (AWH) - 2024 Q4 - Annual Results

Revenue Performance - Record OvaSuite revenue of $9.2 million and volume of 24,305 units sold for the year ended December 31, 2024[1] - Product revenue increased 9.5% to$ 2.3 million for Q4 2024 compared to $2.1 million for Q4 2023[4] - The number of OvaSuite tests performed increased 6.1% to approximately 6,004 in Q4 2024 compared to approximately 5,659 in Q4 2023[4] Profitability - Gross profit margin improved 6.2 percentage points to 63.4% for Q4 2024 compared to 57.2% for Q4 2023[4] Operating Expenses - Total operating expenses decreased by$ 0.4 million, or 8%, to $4.9 million for Q4 2024 compared to the same period in 2023[4] - Total operating expenses for the year ended December 31, 2024, were$ 21.8 million, a decrease of $2.4 million, or 10%, compared to 2023[4] Cash Position - Cash balance as of March 27, 2024, was approximately$ 3.7 million, excluding a pending $1.5 million ARPA-H milestone payment[4] Strategic Initiatives - The company aims to accelerate top-line revenue growth through an improved go-to-market strategy in 2025[5] - The company received a$ 10 million Federal Government investment in ENDOinform, which will support its research and development pipeline[5] Pricing - Average unit price (AUP) decreased 1.0% to $378 for the year ended December 31, 2024, compared to$ 382 for the same period in 2023[4]